June 22, 2005
View Full PaperWhat role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus?
Key Result
Modulation of matrix metalloproteinases (MMP) and their inhibitors (TIMP) may provide new therapeutic avenues for treating cardiomyopathy and vasculopathy in diabetes.
Study Design
Type
Systematic Review
Structured PICO
What role do extracellular matrix changes (MMP and TIMP) contribute to the cardiovascular disease burden of diabetes mellitus?
P
Population
Human subjects with diabetes and experimental animal models with cardiovascular disease (cardiomyopathy and vasculopathy)
I
Intervention
Drug interventions modulating matrix metalloproteinases (MMP) and their inhibitors (TIMP)
O
Outcome
Role of MMPs and TIMPs in cardiomyopathy and vasculopathy in diabetes
Modulation of matrix metalloproteinases and their inhibitors represents a potential therapeutic strategy for managing cardiovascular complications in diabetes.
Abstract
Matrix metalloproteinases (MMP) and their inhibitors (TIMP) are central factors in the control of extracellular matrix turnover. They are important in normal physiology and also during a range of pathological states. In this review, we have systematically identified clinical articles relevant to cardiovascular disease in diabetes from the last 10 years. Our aim was to outline the structure, function and regulation of metalloproteinases and their key roles in cardiomyopathy and vasculopathy in diabetes. We also explore the effects of drug intervention on both human subjects with diabetes and experimental animal models. The modulation of MMP and TIMP activity using drugs that affect the expression and function of these proteins may provide us with new ways to treat this serious and disabling disease, and we explore potential mechanisms and treatments.